Methylene Blue: Another Hidden cure in our dystopian age

Written by Robert Yoho, MD on May 7, 2026. Posted in Current News

Methylene blue (MB), synthesized in 1876, is approved by the Food and Drug Administration (FDA) only for methemoglobinemia but has demonstrated broad antimicrobial, antiviral, and antiparasitic activity across 150 years of clinical use.

• Johns Hopkins researchers identified MB as one of 165 agents with superior activity against stationary-phase Borrelia burgdorferi compared to standard Lyme antibiotics, and subsequent work confirmed comparable potency against persistent Bartonella henselae biofilms.

• MB acts as a urinary antiseptic with a documented record in urinary tract infection (UTI) treatment; chronic low-dose use for UTI prophylaxis has a long clinical history, though formal controlled trials are limited.

• MB is a potent, reversible monoamine oxidase A (MAO-A) inhibitor at nanomolar concentrations, but this is clinically irrelevant for patients not taking serotonergic psychiatric drugs such as SSRIs or SNRIs.

• Oral MB at the low doses now favored by Lyme-literate physicians (4–50 mg twice daily) confers most of the antimicrobial benefit and has a substantial safety margin. Herxheimer reactions occur during MB treatment for Lyme and Bartonella, confirming pathogen kill; starting low and increasing slowly is standard clinical practice.

The molecule that stains everything, including history

In 1876, a German chemist named Heinrich Caro synthesized a vivid blue dye he called methylthioninium chloride. He had no idea he’d produced one of medicine’s most durable workhorses. Within two decades, Paul Ehrlich was using it to stain nerve tissue, and by 1891, Nobel laureate Robert Koch’s colleague Paul Guttmann had administered it to two malaria patients with documented success, making MB the first synthetic compound ever used to treat an infectious disease in humans. This accomplishment is conventionally attributed to the use of sulfa drugs in 1932.

The dye’s career arc since then reads like a long clinical résumé: anesthetic adjunct, cyanide antidote, treatment for methemoglobinemia, surgical staining agent, psychiatric antidepressant (it was used in low doses for mood disorders decades before SSRIs), and now a front-line weapon in the emerging war against persister-phase tick-borne infections. No single molecule spans that breadth.

Persisters are inactive cyst-like variants of the same organism that hang around and wait for favorable conditions to return. They are not easily killed by antibiotics.

MB works through a mechanism called redox cycling. It accepts electrons from one molecule and donates them to another, allowing it to slip into almost any cellular biochemical circuit and either power it up or disrupt it, depending on the target. In human mitochondria, this boosts adenosine triphosphate (ATP) production and reduces oxidative stress. In bacterial and parasitic cells, it does the opposite: it hijacks the electron transport chain, derailing energy production. The compound is, in the language of pharmacology, hormetic: therapeutic at low doses, damaging at high ones. That distinction matters enormously for anyone considering long-term use.

Comment: I’ve been taking MB at low doses as part of my Lyme protocol. What follows here is what I wish I’d had in a single document before I started.

How MB kills bacteria

MB disrupts bacterial energy metabolism through three overlapping mechanisms, any one of which would be useful in chronic infection; together, they’re formidable.

First, it interferes with the electron transport chain in bacterial cell membranes, cutting off ATP synthesis and starving the organism of energy. Second, it generates reactive oxygen species (ROS) inside bacterial cells, which damage deoxyribonucleic acid (DNA), proteins, and lipids simultaneously. Third, and most relevant to chronic Lyme and Bartonella, it penetrates and dismantles biofilms.

Biofilms are dense, self-produced matrices of polysaccharides, proteins, and DNA that bacteria construct as a communal shelter. Borrelia burgdorferi and Bartonella henselae are prolific biofilm producers. Standard antibiotics, which need access to dividing bacterial cells, bounce off these structures. MB somehow gets in anyway.

Conventional antibiotics work best in the log (growth) phase of bacterial proliferation. Once bacteria enter the stationary phase, where growth slows and cells hunker down metabolically, doxycycline and amoxicillin become nearly useless. This is the central reason chronic Lyme is so resistant to standard treatment. MB kills in both phases.

Biofilms are also destroyed by chlorine dioxide, with a few caveats. See the end of this essay for more on that topic.

The Lyme and Bartonella evidence

In 2015, researchers at Johns Hopkins, led by Ying Zhang, screened an FDA drug library against stationary-phase Borrelia burgdorferi. They identified 165 agents with better activity than the “standard-of-care” Lyme antibiotics, doxycycline and amoxicillin, recommended by the corrupt mainstream medicine. MB ranked among the top 52 candidates that killed at least 65% of persister cells and was described as nearly as potent as daptomycin, the agent generating the most excitement in Lyme research at that time.

Other support for methylene blue:

Daptomycin is available only intravenously (IV), is expensive, and is not accessible to most outpatients. MB is oral, cheap, and available at compounding pharmacies.
A 2019 study by the same Hopkins group screened an FDA library against stationary-phase Bartonella henselae and identified 110 candidates superior to another widely used Lyme antibiotic, ciprofloxacin. MB again placed in the top tier.
A follow-up 2020 study in BMC Microbiology tested drug combinations against Bartonella biofilms and found that MB, paired with other antimicrobials, cleared biofilm-recovered cells that no single agent alone could touch.
Rifampin, a standard antibiotic for Bartonella, worked well during the growth phase but failed against stationary-phase organisms. MB does both.

Neither the Borrelia nor the Bartonella studies used animal models or human subjects; they were conducted in cell cultures. What we have is strong in vitro evidence, confirmed mechanistic plausibility, and a growing body of clinician-reported outcomes in patients under clinical care. It is more than we have for many treatments incorporated into standard Lyme protocols.

Comment: My Lyme panel from Vibrant America, drawn in January 2026, showed “active Borrelia burgdorferi with strong immunoglobulin G (IgG) and immunoglobulin M (IgM) bands, Bartonella henselae, and several European Borrelia species.” This sounds terrible to me, but I have hope because my chlorine dioxide and methylene blue theoretically target both persister cells and biofilms. I won’t know for sure how it is working until I check my panel again in a few months and hopefully improve my symptoms.

Babesia

Babesia is a protozoan parasite, not a bacterium, but it’s a common Lyme co-infection, and MB’s antimalarial lineage is directly relevant. Babesia occupies red blood cells much as malaria parasites do, and MB’s mechanism of disrupting intra-erythrocyte energy metabolism that made it an effective antimalarial in 1891 applies here as well. Direct evidence for MB against Babesia in humans is sparse, but the biological rationale is sound and practitioners treating combined Lyme-Babesia infections have incorporated MB into their protocols on that basis.

Antiviral activity

MB inactivates viruses through photodynamic mechanisms: upon light activation, it generates singlet oxygen and other ROS that damage viral nucleic acids and envelope proteins. This property made it valuable early in blood bank sterilization protocols, where it inactivates human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and West Nile virus in plasma products.

The antiviral spectrum extends further than blood banking. MB has shown in vitro activity against yellow fever, dengue, chikungunya, and Ebola. A 2021 study published in the Journal of Clinical Medicine tested MB against two clinically isolated SARS-CoV-2 strains and found that antiviral inhibition was comparable to hydroxychloroquine in cell culture, with synergistic effects when combined with antimalarial compounds.

Note: To show you how hard it is to sort lies from truth in the “scientific literature”, remdesivir, the agent used to murder people during the pandemic, is also mentioned as having profound antiviral activity. I guess when you kill people, there are not going to be any living viruses left inside them.

Evidence of this kind is ignored because Pharma has no financial incentive to pursue a 150-year-old off-patent compound. Whether oral MB at doses used for Lyme disease, 4 to 50 mg twice daily, achieves sufficient systemic concentrations to deliver meaningful antiviral effects in vivo is unknown.

Antiparasitic properties

MB’s original medical use was antiparasitic. Its potency against Plasmodium falciparum, the malaria parasite, was established before quinine became the dominant treatment and has been confirmed repeatedly in modern studies. MB works against both asexual blood-stage parasites and the sexual gametocyte stage, giving it transmission-blocking potential that most antimalarials lack. Resistance to MB in malaria has not emerged as a clinical problem despite over a century of use, unlike almost every modern antimalarial.

Beyond malaria, a patent-protected method covers the treatment of parasitic infections using MB alone or in combination with conventional antiparasitic agents, including protozoan and helminthic (worm) diseases. The proposed mechanism is the same energy disruption that works against bacteria: MB enters parasite mitochondria and collapses the electrochemical gradient required for ATP synthesis. Light activation enhances this effect.

For patients with Lyme co-infections involving protozoal organisms like Babesia, MB’s antiparasitic track record provides additional justification for its inclusion in a comprehensive protocol.

Urinary tract infection: the oldest use you’ve never heard about

Before there were sulfonamides, before there was nitrofurantoin, MB was a urinary antiseptic. It concentrates in urine after oral ingestion (and you see the blue in your toilet bowl), and that concentration gives it direct access to the uroepithelium, where most urinary pathogens establish themselves.

A 2020 randomized controlled trial published in the International Journal of General Medicine studied MB at 20 mg, a dose far below any systemic toxicity threshold. It had measurable antimicrobial activity in the urinary tract and fewer treatment-related adverse events than more complex four-drug combinations.

For chronic UTI prophylaxis, no large controlled trial has established MB as a standalone preventive agent. Its use relies on documented urinary antiseptic properties, the logic that maintaining a dilute MB concentration in the bladder inhibits bacterial colonization, and decades of clinical experience.

Does chronic use produce tolerance or resistance?

Controlled human data on this question do not exist, but the available evidence is reassuring.

MB’s mechanism differs fundamentally from conventional antibiotics. It targets metabolic processes and generates oxidative stress rather than blocking specific biosynthetic pathways. Antibiotic resistance develops when bacteria evolve specific counter-mechanisms: pumps that eject the drug, enzymes that deactivate it, or mutations in the target molecule. None of these pathways neutralize MB’s oxidative attack on the electron transport chain in any known bacterial species.

Malaria, which has evolved resistance to almost every antimalarial thrown at it, has not developed clinically significant resistance to MB despite over a century of use. A reduced therapeutic effect over time requiring a dose increase has not been reported in any clinical series using MB for tick-borne illness. The neuroprotective and mitochondrial-enhancement effects appear to persist with ongoing use.

Whether long-term low-dose MB reduces susceptibility to infectious diseases beyond those being actively treated is unclear. We do know that chronic low-dose MB does not suppress the immune system the way long-term antibiotics do, does not disrupt gut flora with the same severity, and does not select for multi-drug resistant organisms through the same mechanisms.

Dosing, dose-response, and the trend toward lower doses

MB is a hormetic compound. Low doses support mitochondrial function, reduce oxidative stress, enhance cognition, and kill pathogens. High doses reverse every one of those effects, causing mitochondrial dysfunction, oxidative damage, and systemic toxicity. The dose-response curve is not linear; it curves back on itself.

The FDA-approved dosing for methemoglobinemia is 1 to 2 mg/kg by slow IV infusion, repeated once if needed. For Lyme and Bartonella, Lyme-literate practitioners have used a wide range. Dr. Richard Horowitz, whose dapsone-combination protocol has received the most clinical attention, has incorporated MB at 50 mg orally twice daily. Other practitioners, managing patients with complex polypharmacy, have moved to much lower doses in the range of 4 to 16 mg twice daily.

The trend toward lower dosing reflects both growing comfort with the compound and recognition that the dose required for antimicrobial effect does not necessitate high plasma concentrations. Research from the StatPearls database confirms that MB is well tolerated at doses below 2 mg/kg and that adverse effects are considerably worse at doses above 3 mg/kg as a single dose. For a 70 kg adult, that threshold is at 210 mg, well above any oral dose used in Lyme protocols. Oral bioavailability is approximately 72%, and the compound’s lipid solubility allows it to distribute widely into tissues, including the central nervous system.

The half-life is reported variously as 5 to 14 hours, depending on the study, with the most commonly cited figure being approximately 5 hours, supporting twice-daily dosing. Tissue accumulation occurs with repeated dosing, resulting in steady-state concentrations exceeding those predicted from a single dose.

One problem: pulse oximetry interprets MB as deoxygenated hemoglobin, so the device will falsely report a low oxygen saturation (SpO2) for several hours after dosing. Patients using home pulse oximeters or those undergoing anesthesia must communicate this to their care team. A blood gas measurement is accurate; the optical reading is not.

The MAO-A inhibitor issue

MB is a potent, reversible inhibitor of MAO-A, the enzyme that breaks down serotonin, norepinephrine, and several other neurotransmitters in the synapse. A landmark 2007 paper by Rona Ramsay and colleagues demonstrated this in vitro, measuring an inhibitory constant (Ki) of 27 nanomolar. This measures the binding affinity of an inhibitor to an enzyme, representing the concentration required to form a 50% enzyme-inhibitor complex. This one is extraordinarily potent.

For patients not taking serotonergic drugs, this pharmacological fact is clinically irrelevant. MAO-A inhibition generates dangerous consequences only when something is simultaneously flooding the synapse with serotonin. Without that second input, reduced MAO-A activity has no harmful consequence at oral Lyme doses. The serotonin system runs normally; there is simply no toxic interaction to trigger.

The danger is narrow and specific: patients on an SSRI, SNRI, tramadol, meperidine, clomipramine, venlafaxine, or duloxetine who receive IV MB at surgical doses face a serious risk of serotonin syndrome. Serotonin syndrome develops when synaptic serotonin reaches toxic levels, producing a triad of neuromuscular abnormalities (tremor, rigidity, hyperreflexia, myoclonus), autonomic instability (tachycardia, labile blood pressure, hyperthermia, sweating), and altered mental status ranging from agitation to coma. Fatal cases have been documented, solely involving IV administration.

The FDA’s 2011 safety communication discussed IV MB as used during parathyroid surgery at diagnostic doses of 1-8 mg/kg. Every known fatality occurred when patients were already on serotonergic drugs. But the FDA then applied the warning wholesale to oral MB. A review by Fagron Academy of thousands of patients found only one case report that linked oral MB to the serotonin syndrome.

Pharma has a financial incentive to amplify the MAO-A interaction warning because MB, as a cheap off-patent compound, competes with the antidepressant class for the fatigue, brain fog, and mood symptoms that Lyme patients share with the populations to whom SSRIs are marketed. Robert Whitaker documented in his books and at MadInAmerica.com how antidepressant efficacy has been systematically fabricated—no controlled trials using proper placebos exist—while adverse effects, including dependence and long-term outcomes, have been minimized. It is a drug interaction warning that protects a drug class whose net benefits are invisible.

For anyone not on antidepressants or other serotonergic drugs, the MAO-A concern is irrelevant at conventional oral Lyme doses.

Comment: I take no serotonergic drugs. The MAO-A inhibition from oral MB at my doses has no clinical consequence for my situation.

Other side effects and contraindications

G6PD deficiency, a genetic condition, is the primary absolute contraindication. MB requires G6PD to reduce methemoglobin back to hemoglobin; in G6PD-deficient patients, MB paradoxically worsens methemoglobinemia rather than treating it. G6PD deficiency evolved as a malaria-protective adaptation and is concentrated in populations from malaria-endemic regions: sub-Saharan Africa, the Mediterranean, the Middle East, South Asia, and Southeast Asia. Prevalence in white Northern European populations runs at roughly 0.1%, making routine screening in that group a low-yield exercise. G6PD screening before starting MB is appropriate when a patient’s ancestry includes high-prevalence populations; for white Northern Europeans, it is a theoretical footnote rather than a practical requirement.

MB stains urine, stool, and skin blue-green. If you are using drops, be sure to use them with buffered vitamin C and a straw to get them to the back of your throat, or your mouth will stain persistently. These effects are harmless and predictable, but alarming if unexpected.

Nausea and mild gastrointestinal discomfort occur at higher doses. Taking MB with food reduces this. Dizziness and headache have been reported at doses above 50 mg. Hemolysis, the destruction of red blood cells, is not a concern at the low doses used in Lyme protocols (40 mg twice a day).

MB is cleared by the kidneys and reduces blood flow at higher doses, so those with impaired renal function should probably not use methylene blue. Pregnancy is a contraindication given MB’s birth defect potential in animal models and the fetal harm demonstrated following intra-amniotic administration.

Herxheimer reactions

Herxheimer reactions are named for the German dermatologist Karl Herxheimer. He described it in syphilis patients in 1895, and it occurs when rapid microbial die-off releases a flood of bacterial endotoxins, lipoproteins, and other debris that triggers a systemic inflammatory response. In the Lyme community, this is shortened to Herx.

Herx reactions manifest as a temporary worsening of existing symptoms: intensified fatigue, joint pain, headache, sweating, chills, and cognitive fog that develop within hours to days of starting or escalating an antimicrobial. They are, paradoxically, a sign that the treatment is working. They are also miserable.

Project Lyme and several Lyme-literate practitioners have confirmed that MB produces Herx reactions in some patients, consistent with its demonstrated kill effect against Borrelia and Bartonella persister cells. The intensity and timing of the Herx correlate with the targeted bacterial burden and the dose used.

Standard mitigation: start low, around 4–5 mg twice daily, and increase by small increments over weeks rather than jumping to a full treatment dose. Staying well-hydrated supports renal clearance of the released toxins. Some practitioners add binders like activated charcoal or cholestyramine between doses to trap circulating endotoxins, though direct evidence for this in MB-related Herx is anecdotal. If the Herx is severe enough to be debilitating, reduce the dose rather than push through.

Comment: I’ve experienced Herx reactions with MMS1 and fenbendazole running simultaneously, so I know this territory well. Starting MB low is not timidity; it’s intelligent protocol design.